Infections cast cloud over Novartis' MS therapy

@article{Garber2008InfectionsCC,
  title={Infections cast cloud over Novartis' MS therapy},
  author={Ken Garber},
  journal={Nature Biotechnology},
  year={2008},
  volume={26},
  pages={844-845}
}
volume 26 number 8 AuGuST 2008 nature biotechnology Novartis’ small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec’s lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 patients had suffered devastating viral infections, one fatal. Nevertheless, as one of several compounds aiming to become the first orally available drug for MS, FTY720 may still be on track to gain a major slice of the ~$6 billion worldwide market for… CONTINUE READING
BETA

Similar Papers

Loading similar papers…